SHR-4602 for Injection in Subjects With HER2-expressing or -Mutated Unresectable or Metastatic Solid Tumors
NCT06516926
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
240
Enrollment
INDUSTRY
Sponsor class
Conditions
HER2-expressing or -Mutated Unresectable or Metastatic Solid Tumors
Interventions
DRUG:
SHR-4602
Sponsor
Jiangsu HengRui Medicine Co., Ltd.